United States · FDA National Drug Code directory
PANCREAZE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 62541-401_36e934b1-3fbb-8f0c-e063-6294a90a968c
- Product NDC
- 62541-401
- Form
- CAPSULE, DELAYED RELEASE
- Composition / generic term
- PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE
- Labeler
- VIVUS LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20160801
- Source listing expiry
- 20261231
Source-listed ingredients
- PANCRELIPASE LIPASE — 2600 [USP'U]/1
- PANCRELIPASE AMYLASE — 15200 [USP'U]/1
- PANCRELIPASE PROTEASE — 8800 [USP'U]/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BOTTLE, GLASS in 1 CARTON (62541-401-10) / 100 CAPSULE, DELAYED RELEASE in 1 BOTTLE, GLASS · 62541-401-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →